Thrombocytopenia

The FDA granted priority review to pacritinib for treatment of patients with myelofibrosis with severe thrombocytopenia, according to the agent’s manufacturer.

Patients hospitalized with COVID-19 who received high-dose therapeutic anticoagulation appeared to be at increased risk for mortality compared with those on prophylactic anticoagulation, according to a research letter in Thrombosis Research.

This year’s virtual ASH Annual Meeting and Exposition featured hundreds of abstracts that spotlighted research advances in blood cancer and benign hematology research.

Most patients with acute myeloid leukemia who responded to treatment with venetoclax plus azacitidine in the VIALE-A study required dosing modifications to manage cytopenia, according to a presentation from ASH Annual Meeting and Exposition.

Patients acquired myeloproliferative neoplasm driver mutations early in life, often in utero, which then expanded at variable rates over their lifetime before diagnosis, according to study results.

Testing for Heartland virus disease should be part of the evaluation for patients who have an acute febrile illness with either leukopenia or thrombocytopenia that cannot explained by another condition or when a tick-borne disease is suspected, but there was no improvement after appropriate treatment, according to a review of the virus’s epidemiology.

The FDA granted orphan drug designation to avatrombopag for the treatment of chemotherapy-induced thrombocytopenia.

Treatment with Doptelet was cost-effective for the treatment of thrombocytopenia in patients with chronic liver diseases compared with other treatment options, according to data presented at the American Society of Hematology meeting.